Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection

The early administration of anti-SARS-CoV-2 monoclonal antibodies (mAb) could decrease the risk of severe disease and the need of inpatients care. Herein, our clinical experience with Bamlanivimab/Etesevimab for the treatment of early SARS-CoV-2 infection through an outpatient service was described....

Descripción completa

Detalles Bibliográficos
Autores principales: Bavaro, DF, Diella, L, Solimando, AG, Cicco, S, Buonamico, E, Stasi, C, Ciannarella, M, Marrone, M, Carpagnano, F, Resta, O, Carpagnano, GE, Palmieri, VO, Vacca, A, Dell’Aera, M, Dell’Erba, A, Migliore, G, Aricò, M, Saracino, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862158/
https://www.ncbi.nlm.nih.gov/pubmed/35138229
http://dx.doi.org/10.1080/20477724.2021.2024030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862158/
https://www.ncbi.nlm.nih.gov/pubmed/35138229
http://dx.doi.org/10.1080/20477724.2021.2024030

Ejemplares similares